GSK withdrew its EU marketing authorization application for Jesduvroq (daprodustat) earlier this month after the European Medicines Agency’s scientific advisory panel, the CHMP, said the candidate should only be approved in adult patients with anemia resulting from chronic kidney disease (CKD) who are already receiving dialysis.
Safety Concerns Prevented EU Approval For GSK’s Jesduvroq In Non-Dialysis CKD Patients
The European Medicines Agency recommended against the approval of GSK’s Jesduvroq in patients with CKD-related anemia who are not on dialysis because of concerns around its safety profile in these patients.
More from Europe
• By
Cell and gene therapy manufacturers must consider the practicalities of their product within the context of a health care system before it comes onto the market to be successful, experts from Novartis, AstraZeneca and England’s National Health Service say.
• By
Novartis is planning to file EU and US marketing applications for an intrathecal formulation of its spinal muscular atrophy gene therapy, Zolgensma, in H1 2025.
• By
Sponsors of three drugs that are in the final stages of the EU regulatory review cycle are due to make the case for marketing approval before the European Medicines Agency.
• By
Experts working in the advanced therapy space say the US has less strict criteria for regulatory pathways for cell and gene therapies than the EU, particularly for products in early development.
More from Geography
• By
A global collaborative inspections pilot reduced the number of individual inspections for participating manufacturing facilities, demonstrating that multiple regulatory authorities can carry out joint inspections using a mix of on-site and remote approaches.
• By
Novartis is planning to file EU and US marketing applications for an intrathecal formulation of its spinal muscular atrophy gene therapy, Zolgensma, in H1 2025.
• By
A new annual report from China's CDE shows a rise in overall product approvals but a fall in the transition rate for conditional to full approvals, possibly signalling more stringent requirements.